SCHEMBL5455595

SCHEMBL5455595

CCc1ccc(/C(COC)=N/OCc2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TP53 P04637 1/20 0.40
RXRA P19793 3/20 0.39
RXRB P28702 2/20 0.39
ALDH1A1 P00352 2/20 0.38
TDP1 Q9NUW8 2/20 0.37
FFAR1 O14842 1/20 0.37
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
PPARG P37231 4/20 0.36
PPARA Q07869 3/20 0.36
S1PR1 P21453 1/20 0.36
LMNA P02545 1/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
MAPT P10636 1/20 0.35
SLC6A2 P23975 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5455597 1.00 L3MBTL1 (0.41) L3MBTL1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL5469823 0.91 NPC1 (0.43) L3MBTL1NPC1RAB9ASMN1; SMN2RXRA
SCHEMBL5469818 0.91 NPC1 (0.43) L3MBTL1NPC1RAB9ASMN1; SMN2RXRA
SCHEMBL13606730 0.87 L3MBTL1 (0.43) L3MBTL1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL5462367 0.86 NPC1 (0.48) L3MBTL1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL5462371 0.86 NPC1 (0.48) L3MBTL1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL5448525 0.80 MRGPRX4 (0.39) L3MBTL1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL5448523 0.80 MRGPRX4 (0.39) L3MBTL1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL5448519 0.80 L3MBTL1 (0.41) L3MBTL1NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL5448513 0.80 L3MBTL1 (0.41) L3MBTL1NPC1RAB9ASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420679-B2 Aminothiazole derivatives and their use as CRF receptor ligands SANOFI (FR) 2013-04-16 US disclosed
US-20070281919-A1 Aminothiazole Derivatives And Their Use As CRF Receptor Ligands SANOFI-AVENTIS (FR) 2007-12-06 US disclosed
EP-1200419-B1 AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS SANOFI SYNTHELABO (FR) 2004-04-14 EP disclosed
US-6586456-B1 Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide SANOFI-SYNTHELABO (FR) 2003-07-01 US disclosed
EP-1200419-A1 AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS SANOFI-SYNTHELABO (FR) 2002-05-02 EP disclosed
WO-2001005776-A1 AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS SANOFI-SYNTHELABO (FR) 2001-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281919-A1 Aminothiazole Derivatives And Their Use As CRF Receptor Ligands CRH, CRHR1, CRHR2 L3MBTL1 4770/4885NPC1 2994/4885RAB9A 3096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.